Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →BioSpace headline: 'Deaths Lead Boehringer Ingelheim to Cancel $730 Million Cancer Deal With Hanmi Pharma, Hanmi Stock Tanks' — explicit safety-driven…
Labiotech characterised the overseas patient deaths as 'a blow to Boehringer Ingelheim,' positioning the termination as a setback to BI's oncology pipeline…
Fierce Biotech declared olmutinib a 'troubled Tagrisso rival' after Hanmi's April 2018 formal development termination — a definitive negative verdict on the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Boehringer Ingelheim acquired exclusive ex-Korea/China/Hong Kong rights to Hanmi's third-generation EGFR TKI HM61713 for $50M upfront and up to $680M in milestones plus tiered double-digit royalties. Boehringer terminated the deal September 30, 2016 following clinical safety signals (interstitial lung disease deaths).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim International GmbH / Hanmi Pharmaceutical Co., Ltd. (HM61713 program) (this deal) | 2015 | $730M | — |
| Boehringer Ingelheim International GmbH / Sanofi SA (Merial Animal Health) | 2015 | $12.4B | 81 |
| Boehringer Ingelheim International GmbH / Abexxa Biologics Inc. | 2021 | — | — |
| Boehringer Ingelheim International GmbH / T3 Pharmaceuticals AG | 2023 | $508M | — |
| Boehringer Ingelheim International GmbH / Cue Biopharma, Inc. | 2025 | $357M | — |
| Boehringer Ingelheim International GmbH / Synaffix B.V. | 2025 | $1.3B | — |
| Boehringer Ingelheim International GmbH / Immunitas Therapeutics, Inc. | 2026 | — | — |
← Browse all deals · How we score deals
More: 2015 deals · Boehringer Ingelheim International GmbH deals · Oncology deals